Newswise — BERLIN (April 10, 2013) – In "Innovations in Neuromodulation," the International Neuromodulation Society (INS) brings together over 200 entrepreneurs, thought leaders, innovators and investors on June 9, 2013 to focus on developments in this rapidly changing field. The day includes:
• Executives presenting from 13 innovative, early-stage neuromodulation companies:
Aleva Neurotherapeutics, SAAlgostim, LLCBiotectix, LLCEndoStimFunctional Neuromodulation, Ltd.Mainstay Medical, Inc.NeuroNexus Neuros Medical, Inc.Neurosigma, Inc. Neurotargeting, LLCNexstim OyStimwave Technologies, Inc.W.I.S.E., S.r.l
• Regulatory pathways and winning strategies moderated by INS Past President Dr. Elliot Krames and President Dr. Simon Thomson• What big companies look for when they buy small companies – panel discussion with representatives from Boston Scientific Corporation, Johnson & Johnson, Medtronic, Inc., and Sorin Group• How to raise money for a startup by Nevro Corp. Chief Business Officer Rami Elghandour• Insight into the innovation process, intellectual property, industry trends, market penetration and forecasts by serial entrepreneur Dr. Danny Sachs• Intelligence on medical device investment strategies and challenges; enabling neuroscience and emerging therapies, companies, and platforms; global industry alliances and acquisitions by Dr. Eric Grigsby, CEO, Neurovations; medical director, Napa Pain Clinic• Trends in CE Mark and FDA regulatory approvals in Europe and the U.S. by regulatory affairs strategist Winifred Wu• Evidence for payers by Rod Taylor, Ph.D., professor in Health Services Research• A keynote speech by Chris Chavez, chairman, president and CEO, TriVascular, Inc. and former CEO and director, Advanced Neruomodulation Systems, Inc. • Networking with medical device industry leaders and emerging therapy innovators
The talks precede scientific sessions at the INS 11th World Congress. “Technology Transforming Chronic Illness Management” at the Estrel Hotel in Berlin, Germany, June 8 - 13, 2013, with comprehensive tracks on all neuromodulation therapies: http://www.neuromodulation.com/ins-congress.
7:45 – 8:00 Welcome and Opening RemarksINS Past President Dr. Elliot Krames, and INS President Dr. Simon Thomson8:00 – 8:30 Neuromodulation: Analysis of the Industry and Global Market Dr. Eric Grigsby, CEO, Neurovations; medical director, Napa Pain Clinic8:30 – 9:30 Emerging Company Presentations: Enabling Therapy DeliveryHighlights the critical role of interfacing with neural tissue in effective neuromodulation and the innovation focused in this critical area. 9:30 – 10:00 Formalizing Ideas and Protecting Intellectual PropertyDr. Danny Sachs, founder of Respicardia, Mainstay, Kspine, & Amphora10:00 – 10:30 Networking with medical device industry leaders and emerging therapy innovators10:30 – 11:20 Emerging Company Presentations: Innovation PlatformsHighlights the development of foundational platforms that will enable others to develop novel therapeutic solutions through leverage of a flexible platform. 11:20 – 12:00 How to raise money for a startup Nevro Corp. Chief Business Officer Rami Elghandour12:00 – 13:00 Keynote speech Chris Chavez, chairman, president and CEO, TriVascular, Inc. and former CEO and director, Advanced Neruomodulation Systems, Inc.13:30 – 14:30 Emerging Company Presentations: Externals and PlanningHighlights the role of external instrumentation in the delivery of neuromodulation. This group includes companies providing systems that stimulate the various targets throughout the nervous system, as well as enable more effective chronic stimulation through image-guided planning and therapy.Dr. Krames, moderator14:30 – 15:30 Regulatory Pathway: FDA Approval and CE Mark DesignationDr. Thomson, moderator14:30 – 14:55 Regulatory Approval Requirements – U.S. and European Commission – Recent TrendsWinifred Wu, president, Strategic Regulatory Partners, LLC15:20 – 15:30 Evidence for PayersHealth Services Research Professor Rod Taylor, Ph.D., Exeter University15.30 – 16.30 Emerging Company Panel Presentations: New Therapy DevelopmentHighlights those who focus on creating new therapeutic solutions through neuromodulation.Dr. Krames, Moderator17:00 – 17:50 What Big Companies Look for When They Buy Small CompaniesDon Deyo, CEO, MedTech Execs, and former vice president of R&D, Medtronic Neuromodulation, moderator17:00 – 17:10 Boston Scientific Corporation: Michael Ryan, director, Business Development17:10 – 17:20 Codman Neuro, division of Johnson & Johnson: Peter Stebbins, vice president, Business Development17:20 – 17:30 Medtronic, Jeff Erb, senior director of Business Development, Alliances and IP Portfolio Management17:30 – 17:40 Sorin Group: Catherine Picard, vice president, New Ventures
About the International Neuromodulation Society (INS) The INS is a nonprofit group of clinicians, scientists and engineers dedicated to scientific development and knowledge of neuromodulation, a rapidly growing family of therapies developed to help relieve pain or restore function by delivering electromagnetic stimulation or chemical agents to specific sites in the body. Founded in 1989 and based in San Francisco, Calif., the INS has 15 current and four forming chapters worldwide, and educates and promotes the field through meetings, its journal Neuromodulation: Technology at the Neural Interface, and chapter websites. For more information, please visit www.neuromodulation.com.